CN Patent

CN120548176A — 多胺途径抑制剂药物与脯氨酸/精氨酸饮食限制的组合

Assigned to Zurich Universitaet Institut fuer Medizinische Virologie · Expires 2025-08-26 · 1y expired

What this patent protects

在一个方面中，本发明涉及二氟甲基鸟氨酸(DFMO)在治疗癌症中的用途。向接受旨在降低脯氨酸、精氨酸、或二者的血浆水平的饮食方案和/或药物治疗的患者施用该药物。

USPTO Abstract

在一个方面中，本发明涉及二氟甲基鸟氨酸(DFMO)在治疗癌症中的用途。向接受旨在降低脯氨酸、精氨酸、或二者的血浆水平的饮食方案和/或药物治疗的患者施用该药物。

Drugs covered by this patent

eflornithine-hydrochloride (EFLORNITHINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN120548176A
Jurisdiction: CN
Classification: —
Expires: 2025-08-26
Drug substance claim: No
Drug product claim: No
Assignee: Zurich Universitaet Institut fuer Medizinische Virologie
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.